罗氏雅美罗获得美国 FDA 突破性疗法资格

罗氏雅美罗获得美国 FDA 突破性疗法资格，用于治疗系统性硬化症, 多个新研究结果在 EULAR 2015 上公布。 1. 针对托珠单抗治疗系统性硬化症的临床研究-——全球 3 期临床试验已启动。...

FDA breakthrough therapy qualification, for the treatment of systemic sclerosis, multiple new research results in EULAR 2015 released. 1 for tocilizumab treatment of systemic sclerosis clinical research -- the global phase 3 clinical trial has been started. ...